New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:16 EDTADI, EWG, IBN, HBI, ABC, CYTKHigh option volume stocks: HBI ABC CYTK ADI EWG IBN
News For HBI;ABC;CYTK;ADI;EWG;IBN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
10:00 EDTABCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:13 EDTABCAmerisourceBergen downgraded to Hold from Buy at ISI Group
Subscribe for More Information
07:38 EDTABCAmerisourceBergen price target raised to $93 from $85 at Cowen
Subscribe for More Information
October 30, 2014
16:10 EDTCYTKCytokinetics sees FY14 cash revenues $19M-$21M
Subscribe for More Information
16:09 EDTCYTKCytokinetics reports Q3 EPS (16c), consensus (24c)
Reports Q3 revenue $9.4M, consensus $7.38M.
10:26 EDTHBIHigh option volume stocks
Subscribe for More Information
07:16 EDTABCAmerisourceBergen sees FY15 continuing ops EPS $4.36-$4.50, consensus $4.38
Subscribe for More Information
07:15 EDTABCAmerisourceBergen reports Q4 adjusted EPS $1.10, consensus $1.05
Subscribe for More Information
October 29, 2014
16:08 EDTHBIHanesbrands raises FY14 adjusted EPS view to $5.55-$5.65 from $5.40-$5.60
Subscribe for More Information
16:07 EDTHBIHanesbrands reports Q3 adjusted EPS $1.73, consensus $1.68
Subscribe for More Information
15:53 EDTHBINotable companies reporting after market close
Subscribe for More Information
15:41 EDTABCNotable companies reporting before tomorrow's open
Subscribe for More Information
October 27, 2014
07:39 EDTCYTKCytokinetics provides development program update for omecamtiv mecarbil
Cytokinetics provided an update relating to omecamtiv mecarbil, the company's lead drug candidate from its cardiac muscle contractility program. The company announced that COSMIC-HF, or Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure, has enrolled over 275 patients towards the objective of 450 patients in the ongoing expansion phase of the trial. In addition, over 70 patients have completed the 20 weeks of dosing in the expansion phase of COSMIC-HF. Recently, the Data Monitoring Committee reviewed data from COSMIC-HF and recommended that the trial continue without any changes to the protocol. Patient enrollment in COSMIC-HF is expected to conclude by the end of 2014. The company also announced that CY 1211, a Phase I study comparing the tolerability and pharmacokinetics of omecamtiv mecarbil between Japanese and Caucasian healthy volunteers, is complete and indicates no clinically meaningful differences between the two groups studied. Data from CY 1211 are expected to inform plans for the development of omecamtiv mecarbil in Japan and the inclusion of Japan in potential global Phase III program activities.
October 24, 2014
08:03 EDTABCAmerisourceBergen selects Qlik Technologies for enterprise deal
Subscribe for More Information
October 20, 2014
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use